"The future favors the brave." ...

Good day, and thank you for standing by. Welcome to the Myriad Genetics fourth quarter 2024 financial earnings conference call. (Operator Instructions) Please be advised that today's conference is ...

2025 Adjusted Operating Cash Flow Target: $20 million to $30 million. Myriad Genetics Inc (NASDAQ:MYGN) achieved 11% revenue growth in 2024 compared to 2023, driven by volume and revenue per test ...

(RTTNews) - Below are the earnings highlights for Myriad Genetics Inc. (MYGN): Earnings: -$42.5 million in Q4 vs. -$31.2 million in the same period last year. EPS: -$0.47 in Q4 vs. -$0.36 in the ...

Good day, and thank you for standing by. Welcome to the Myriad Genetics Fourth Quarter 2024 Financial Earnings Conference Call. At this time, all participants are in a listen-only mode.

Good day, and thank you for standing by. Welcome to the Myriad Genetics fourth quarter 2024 financial earnings conference call. (Operator Instructions) Please be advised that today's conference is ...

Myriad Genetics Stock Down 0.6 % Shares of MYGN opened at $14.56 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90. Myriad Genetics, Inc ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Myriad Genetics and Lumea Inc. partner to integrate molecular diagnostics into Lumea's digital pathology platform, enhancing cancer care efficiency. Myriad Genetics and Lumea Inc. have announced a ...

Myriad Genetics, Inc. is a molecular diagnostic company, which focuses on developing and marketing of novel predictive and personalized medicines and prognostic medicine tests. It operates through ...